NervGen Pharma (NASDAQ:NGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Cerbat Gem

Shares of NervGen Pharma (NASDAQ:NGEN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $18.00.

Several brokerages have issued reports on NGEN. Wall Street Zen upgraded NervGen Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 29th. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Weiss Ratings started coverage on NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating for the company. TD Cowen assumed coverage on NervGen Pharma in a report on Thursday, June 11th. They set a “buy” rating for the company. Finally, Zacks Research raised NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th.

Read Our Latest Research Report on NervGen Pharma

NervGen Pharma Stock Performance

NGEN stock opened at $2.12 on Monday. NervGen Pharma has a 12 month low of $1.70 and a 12 month high of $6.30. The business’s 50-day moving average price is $2.62. The stock has a market cap of $170.94 million and a PE ratio of -23.56.

NervGen Pharma (NASDAQ:NGEN – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

(Get Free Report)

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.

Featured Articles